TDMS No. 93020 - 03	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Reqsted: 08/08/2005
Test Type: 90-DAY Route: SKIN APPLICATION Species/Strain: RATS/F 344	CAS Number: 693-13-0 Pathologist: BIERLEY, B STEDHAM, M SHANAHAN, P. Final #2/Rats	Time Report Reqsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA
	Final #2/Rais	
C Number:	C93020	
Lock Date:	05/16/1995	
Cage Range:	ALL	
Date Range:	ALL	

- Reasons For Removal: ALL
- Removal Date Range: ALL
- Include ALL **Treatment Groups:**

- a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Regsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

CAS Number: 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Regsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/K
Disposition Summary						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths Moribund Sacrifice Natural Death					10	3 7
Survivors Terminal Sacrifice Animals Examined Microscopically	10 10	10 10	10 10	10 10	10	10
ALIMENTARY SYSTEM						
Liver Centrilobular, Congestion Centrilobular, Vacuolization Cytoplasmic	(10)	(0)	(0)	(10)	(10) 4 [1.5] 1 [1.0]	(10) 6 [2.3] 6 [1.5]
Periportal, Vacuolization Cytoplasmic Pancreas	1 [1.0] (10)	(0)	(0)	(10)	(10)	(9)
Acinus, Atrophy, Focal Stomach, Glandular Infiltration Cellular, Mixed Cell Cyst	1 [1.0] (10)	(0)	(0)	(10) 1 [1.0] 1 [2.0]	(10)	(10)
CARDIOVASCULAR SYSTEM						
Heart Cardiomyopathy Artery, Inflammation, Chronic Active	(10) 4 [1.3]	(10) 4 [1.0]	(10) 6 [1.0]	(10) 4 [1.0]	(10) 5 [1.2] 1 [1.0]	(10) 3 [2.7]
ENDOCRINE SYSTEM						
None						

None

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Reqsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

CAS Number: 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Reqsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/K
GENITAL SYSTEM						
Preputial Gland Inflammation, Chronic Active	(10) 2 [2.0]	(0)	(0)	(10) 2 [2.5]	(10) 1 [2.0]	(10) 4 [1.3]
HEMATOPOIETIC SYSTEM						
Bone Marrow Hemorrhage	(10)	(0)	(0)	(10)	(10)	(10) 2 [2.5]
Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Plasma Cell	(10) 1 [2.0] 1 [2.0]	(0)	(0)	(10)	(10)	(10)
Hemorrhage Lymph Node, Mesenteric	(10)	(0)	(0)	1 [1.0] (10)	(10)	(10)
Necrosis Spleen Lymphoid Follicle, Depletion Cellular	1 [1.0] (10)	(10)	(10)	(10)	(10)	(10) 1 [2.0]
Thymus Necrosis Hemorrhage	(10)	(10)	(10)	(10)	(10) 2 [2.0] 2 [2.5]	(10)
Atrophy					2 [2.5]	3 [2.3]
NTEGUMENTARY SYSTEM						
Skin Epidermis, Skin, Site Of Application, Hyperplasia	(10)	(10) 5 [1.0]	(10) 7 [1.0]	(10) 10 [1.6]	(10) 10 [2.0]	(10) 3 [2.3]
Epidermis, Skin, Site Of Application, Necrosis, Focal						9 [2.9]
Skin, Site Of Application, Inflammation, Chronic Active				1 [1.0]	7 [1.7]	10 [2.8]

None

NERVOUS SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Regsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

CAS Number: 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Regsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Brain Edema, Focal Hemorrhage Congestion	(10)	(10)	(10)	(10)	(10) 5 [1.0] 1 [1.0]	(10) 1 [1.0] 4 [2.3] 1 [3.0]
Arteriole, Necrosis, Fibrinoid Neuron, Necrosis					8 [2.6]	1 [1.0]
RESPIRATORY SYSTEM						
Lung Congestion Hemorrhage Alveolus, Infiltration Cellular, Histiocyte	(10)	(0)	(0)	(10)	(10) 5 [2.8] 1 [2.0] 1 [1.0]	(10) 8 [2.8]
Interstitium, Inflammation, Chronic Active Perivascular, Infiltration Cellular,	1 [1.0] 3 [1.7]			6 [1.0]	1 [2.0] 1 [2.0]	
Lymphocyte Nose Respiratory Epithelium, Inflammation, Chronic Active	(10) 3 [1.3]	(0)	(0)	(10) 1 [1.0]	(10) 1 [2.0]	(10) 5 [1.4]
Respiratory Epithelium, Metaplasia, Squamous Squamous Epithelium, Inflammation,				1 [1.0]		3 [1.7]
Chronic Squamous Epithelium, Inflammation, Chronic Active				1 [1.0]		1 [2.0]
SPECIAL SENSES SYSTEM						
Eye Cornea, Bilateral, Degeneration, Focal	(0)	(0)	(0)	(0)	(1) 1 [2.0]	(0)
URINARY SYSTEM						
Kidney Nephropathy	(10) 5 [1.0]	(0)	(0)	(10) 2 [1.0]	(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

P18: INCIDENCE	Date Report Reqsted: 08/08/2005						
				Time Report Reqsted: 08:53:32			
	CAS Numł	per: 693-13-0		First Dose M/F: 09/06/94 / 09/07/94			
Pathologist: BIERLEY, B STEDHAM, M SHANAHAN, P.				Lab: MBA			
0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG		
-	Patho	WITH AVERAGE SI DIISOPROPYL CAS Numl Pathologist: BIERLEY, B S	WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE CAS Number: 693-13-0 Pathologist: BIERLEY, B STEDHAM, M SHANAH	DIISOPROPYLCARBODIIMIDE CAS Number: 693-13-0 Pathologist: BIERLEY, B STEDHAM, M SHANAHAN, P.	WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDETime Report Reqsted: First Dose M/F: 09/06/9CAS Number: 693-13-0First Dose M/F: 09/06/9Pathologist: BIERLEY, B STEDHAM, M SHANAHAN, P.Lab: MBA		

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Reqsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

CAS Number: 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Reqsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/K
Disposition Summary						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths Moribund Sacrifice					10	10
Survivors						10
Accidently Killed	1					
Terminal Sacrifice	9	10	10	10		
Animals Examined Microscopically	10	10	10	10	10	10
ALIMENTARY SYSTEM						
Liver	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					1 [1.0]	0.14.01
Centrilobular, Congestion Mesentery	(0)	(0)	(0)	(1)	(0)	2 [1.0] (0)
Fat, Necrosis	(0)	(0)	(0)	(1) 1 [3.0]	(0)	(0)
Pancreas	(10)	(0)	(0)	(10)	(10)	(10)
Acinus, Cytoplasmic Alteration, Focal	1 [2.0]	()			, , ,	()
CARDIOVASCULAR SYSTEM						
Heart	(10)	(10)	(10)	(10)	(10)	(10)
Cardiomyopathy			1 [1.0]	2 [1.0]	2 [1.0]	
ENDOCRINE SYSTEM						
Adrenal Cortex	(10)	(0)	(0)	(10)	(10)	(10)
Hypertrophy, Focal	1 [2.0]				· · /	. ,

None

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Regsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

CAS Number: 693-13-0

Route: SKIN APPLICATION Species/Strain: RATS/F 344

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Regsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/K
Clitoral Gland	(8)	(0)	(0)	(6)	(10)	(10)
Inflammation, Chronic Active Ovary	(10)	(0)	(0)	1 [1.0] (10)	2 [1.0] (10)	1 [1.0] (10)
Cyst Uterus Hydrometra	(10)	(1)	(5) 5 [3.4]	1 [2.0] (10) 4 [2.8]	(10)	(10) 1 [2.0]
IEMATOPOIETIC SYSTEM						
Bone Marrow Hyperplasia, Focal, Lymphoid Hyperplasia, Focal, Histiocytic	(10)	(0)	(0)	(10) 1 [1.0] 2 [1.5]	(10)	(10)
Hemorrhage Atrophy				_[]	1 [1.0] 1 [1.0]	2 [2.0]
Lymph Node, Mandibular Hemorrhage	(10)	(0)	(0)	(9)	(9) 1 [2.0]	(10)
Hyperplasia, Lymphoid Lymph Node, Mesenteric Hyperplasia, Histiocytic	(10) 1 [2.0]	(0)	(0)	(10) 1 [2.0]	1 [2.0] (10)	2 [2.0] (10)
Hyperplasia, Lymphoid Thymus Atrophy	(10)	(10)	(10)	1 [3.0] (10)	(10) 4 [2.3]	(10) 1 [3.0]
NTEGUMENTARY SYSTEM						
Skin Epidermis, Skin, Site Of Application,	(10) 1 [1.0]	(10) 2 [1.0]	(10) 3 [1.0]	(10) 5 [1.0]	(10) 10 [1.4]	(10) 10 [2.8]
Hyperplasia Epidermis, Skin, Site Of Application,						10 [1.6]
Necrosis, Focal Skin, Site Of Application, Inflammation, Chronic Active					7 [1.0]	10 [3.7]

None

NERVOUS SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Reqsted: 08/08/2005

WITH AVERAGE SEVERITY GRADES[b] DIISOPROPYLCARBODIIMIDE

130FROF I LOARBODIII

CAS Number: 693-13-0

Species/Strain: RATS/F 344

Route: SKIN APPLICATION

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Time Report Reqsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Brain Edema, Focal Hemorrhage Arteriole, Necrosis, Fibrinoid Neuron, Necrosis	(10)	(10)	(10)	(10)	(10) 5 [1.0] 5 [2.2] 1 [1.0] 8 [2.4]	(10) 2 [1.0] 6 [2.0] 2 [4.0]
RESPIRATORY SYSTEM						
Lung Congestion Hemorrhage	(10)	(0)	(0)	(10)	(10) 5 [1.8] 1 [2.0]	(10) 8 [2.5]
Interstitium, Inflammation, Chronic Active Perivascular, Infiltration Cellular, Lymphocyte	1 [2.0] 4 [1.3]			3 [1.7] 5 [2.4]	4 [2.3]	
Nose Olfactory Epithelium, Atrophy Olfactory Epithelium, Inflammation, Chronic Active	(10) 1 [1.0]	(0)	(0)	(10) 1 [1.0]	(10)	(10)
Respiratory Epithelium, Atrophy Respiratory Epithelium, Inflammation, Chronic Active	1 [1.0]				1 [1.0]	2 [1.0]
Squamous Epithelium, Inflammation, Chronic Active					1 [1.0]	
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney Congestion	(10)	(0)	(0)	(10)	(10) 1 [2.0]	(10) 1 [2.0]
Medulla, Mineralization Urinary Bladder Serosa, Mineralization	5 [1.0] (10)	(0)	(0)	6 [1.0] (10) 1 [2.0]	10 [1.0] (10)	3 [1.0] (10)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 93020 - 03	P18: INCIDENCE	Date Report Reqsted: 08/08/2005				
Test Type: 90-DAY			EVERITY GRADES[b] _CARBODIIMIDE		Time Report Reqsted:	08:53:32
Route: SKIN APPLICATION		CAS Numb	ber: 693-13-0		First Dose M/F: 09/06/9	4 / 09/07/94
Species/Strain: RATS/F 344	Patho	Lab: MBA				
FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)